Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | BLVRB | P30043 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | PPID | Q08752 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525684 | 0.91 | — | — | |
| SCHEMBL3533045 | 0.84 | ABCC4 (0.31) | ABCC4ABCB11PGRCHRM1PDE4A | |
| SCHEMBL3530670 | 0.82 | FNTA (0.35) | ABCC4ABCB11PGRCHRM1PDE4A | |
| SCHEMBL3528585 | 0.82 | PGGT1B (0.33) | PPARD | |
| SCHEMBL3529648 | 0.81 | TRPM8 (0.36) | — | |
| SCHEMBL3526198 | 0.79 | PPARD (0.33) | PPARDABCC4ABCB11PGRCHRM1 | |
| SCHEMBL3530461 | 0.76 | XDH (0.33) | ABCC4ABCB11PGRCHRM1PDE4A | |
| SCHEMBL3533800 | 0.76 | XDH (0.34) | ABCC4ABCB11PGRCHRM1PDE4A | |
| SCHEMBL3532538 | 0.76 | FNTA (0.37) | ABCC4ABCB11PGRCHRM1PDE4A | |
| SCHEMBL3530081 | 0.76 | FNTA (0.37) | ABCC4ABCB11PGRCHRM1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931337-B1 | PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-7709481-B2 | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261979-A1 | Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals | PPARD, PPARA, PPARG | PPARD 1/4885ABCC4 362/4885ABCB11 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.